Orbis and Heidelberg Engineering announce new partnership at ESCRS congress

News
Article

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

The imaging company will also provide funding to retinoblastoma research.

The imaging company will also provide funding to retinoblastoma research.

On Friday, Orbis, a global charity dedicated to fighting avoidable blindness, announced a partnership programme with Heidelberg Engineering. The announcement was made during the 41st ESCRS annual meeting. In a press release, Orbis announced the collaboration will make use of its e-learning and telemedicine platform Cybersight to train eyecare professionals.

The global mission of Orbis seeks to serve the majority of people with vision loss and blindness; according to the non-profit, 90% of the 1.1 billion people affected live in low- or middle-income countries. Heidelberg Engineering will support live webinars via the Heidelberg Engineering Academy, with new sessions on optical coherence tomography (OCT) and related imaging technologies.

The company will also fund new research on retinoblastoma. This rare retinal cancer most commonly affects 9,000 paeditatric patients worldwide each year, most of whom are under 5 years of age. In a statement, Orbis said 92% percent of children diagnosed live in low- and middle-income countries. Barriers such as late diagnosis, limited accessibility to eye care, and lack of resources contribute to a 40% survival rate within 3 years of diagnosis.

Dr Hunter Cherwek, Vice President, Clinical Services & Technologies at Orbis International, said, “Orbis is delighted to be partnering with Heidelberg Engineering. Retinoblastoma outcomes for children in low-and-middle income countries could be significantly improved with earlier diagnosis and enhanced treatment.”

“As a global leader in imaging and health care technology, Heidelberg Engineering’s generous contribution and partnership will mean we can both offer enhanced knowledge for eye care practitioners via Cybersight, and pioneer new research that will help improve outcomes for children facing retinoblastoma across the world,” Dr Cherwek added.

Reference

1. Leading eye care charity Orbis announces a new partnership with Heidelberg Engineering. News release. Orbis UK. Published 8 September, 2023.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
Related Content
© 2025 MJH Life Sciences

All rights reserved.